Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were exposed to Stelara (ustekinumab) or Tremfya (guselkumab) at any point during pregnancy, or within 3 months before the first day of their last menstrual period, regardless of how long they took it, the dose, or how many times.
- People for whom there is a record of exactly when during the pregnancy the exposure to Stelara (ustekinumab) or Tremfya (guselkumab) occurred.
Who may not be able to join:
- People who were not exposed to Stelara (ustekinumab) or Tremfya (guselkumab) during pregnancy or within 3 months before the first day of their last menstrual period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christina Chambers, PhD, MPH, University of California, San Diego
Phone: 877-311-8972
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Major structural malformations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.